Section 1 Case 1 A Yemeni boy was born healthy at full term after an uncomplicated pregnancy and delivery. Head circumference (HC) at birth is unknown. At 3 months of age, he developed vomiting and failure to thrive. He was diagnosed with renal tubular acidosis (RTA). Targeted DNA analysis revealed ATP6V0A4 mutations associated with autosomal recessive distal RTA. Around 12 months of life, the patient developed horizontal nystagmus. At that time, his HC and height were approximately 10th percentile for age (45 cm and 74.9 cm, respectively). His development, the remainder of his neurologic examination, and brain MRI were normal. There were no birthmarks. He was lost to follow-up until 30 months of age, when he developed leg pain, progressive weakness of the lower, then upper extremities, dysarthria, decline in language skills, and sensorineural hearing loss following a mild viral illness. Examination at 30 months revealed normal muscle bulk, hypotonia, hyporeflexia, weakness (4/5 muscle strength throughout), and a wide-based gait. Bilateral wrist drop, finger contractures, decreased muscle bulk, and microcephaly (HC 2nd percentile, 46 cm) were noted at 53 months of age.
Section 2
These siblings presented with childhood-onset progressive distal and proximal muscle weakness, hyporeflexia, nystagmus, optic atrophy, hearing loss, gastroesophageal reflux, failure to thrive, and developmental regression, suggestive of combined peripheral nervous system and CNS involvement. The differential diagnosis is shown in table 1 and includes metabolic disorders, riboflavin transporter deficiency, infantile neuroaxonal dystrophy, or spinal muscular atrophy. Other investigations and results for both patients are listed in table 2.
The boy underwent extensive evaluations (tables 1 and 2). The newborn screen revealed risk for short chain acylCoA dehydrogenase deficiency and isobutyryl Co-A dehydrogenase deficiency. Urine organic acid analysis revealed ethylmalonic aciduria (SCAD deficiency/mitochondrial dysfunction). The acylcarnitine profile showed mild elevation of propionylcarnitine (C3), butyryl/isobutyryl carnitine (C4) (SCAD or isobutyryl CoA dehydrogenase deficiency), and octanoyl carnitine (C8) (MCAD deficiency). These findings can also occur in riboflavin transporter deficiency. EMG/ nerve conduction studies of both lower extremities revealed a motor axonal polyneuropathy without acute denervation (tables 1 and 2). Muscle biopsy revealed widespread myofiber atrophy with mild fiber-type grouping and a marked increase in esterase staining, suggestive of a neurogenic pathology (figure 2). Staining for succinate dehydrogenase and cytochrome C oxidase showed occasional small foci of subsarcolemmal staining in scattered fibers, which is nonspecific, or suggestive of mitochondrial dysfunction. His brain MRI and magnetic resonance spectroscopy revealed mild nonspecific changes (tables 1 and 2).
Due to the similarities between the siblings' clinical manifestations, the sister's evaluation was limited (table 2) .
Questions for consideration 1. Based on these findings, what is the differential diagnosis? 2. What testing could clarify the diagnosis? 
Section 3
The differential diagnosis for these patients can be narrowed to infantile neuroaxonal dystrophy, a mitochondrial disorder, or riboflavin transporter deficiency.
PLA2G6 gene testing for infantile neuroaxonal dystrophy was negative. Mitochondrial respiratory chain enzyme analysis was unremarkable. A peripheral nerve biopsy of the boy showed severe axonal neuropathy with variable degeneration. Visual evoked potentials of both were abnormal without reproducible P100 peaks. Auditory evoked potential testing showed absent responses, suggestive of an auditory neuropathy. Given the evidence for the motor, sensory, and cranial neuropathies, both children received occupational and physical therapies, and were treated empirically for possible riboflavin deficiency and mitochondrial disorder, with 30 mg/kg/ d of riboflavin, 4 mg/kg/d of coenzyme Q10, and 330 mg TID of carnitor. Whole exome sequencing was initially deferred due to cost.
By 5 years of age, both children developed mild scoliosis, diffuse muscle atrophy, and extensor posturing of the upper extremities with bilateral hand contractures. They were referred to the NIH undiagnosed disease program when patient 1 was 5.5 years old; they were initially evaluated at NIH when patient 1 was 6 years of age. In addition to their known ATP6V0A4 gene mutations (RTA), whole exome sequencing also revealed homozygous gene variants in TOP1MT (a mitochondrial DNA topoisomerase, c.1030C>T), PLEC1 (a gene associated with epidermolysis bullosa, limb-girdle muscular dystrophy type 2Q, and pyloric atresia, c.5843 G>A), and homozygous c.1327T>C (p, C443R) mutations in the SLC52A2 gene (a riboflavin/vitamin B 2 transporter gene). The mutations in the SLC52A2 gene have not been previously described, but are believed to be causative of the rare diagnosis of Brown-Vialetto-Van-Laere syndrome (BVVLS) type 2.
The healthy eldest sister, who has the infant daughter with microcephaly, was sequenced and subsequently found to be a carrier of the ATP6V0A4, SLC52A2, and PLEC1 genes. She is also homozygous for the TOP1MT gene mutation. She is married to her maternal first cousin.
Discussion BVVLS is a rare neurologic disorder with motor (limb, neck, and respiratory muscle weakness), sensory (gait ataxia), and cranial neuropathies (bulbar palsy, hearing loss, facial weakness, optic atrophy, and nystagmus) due to riboflavin transporter deficiency. BVVLS1 is caused by mutations in C20orf54/SLC52A3 gene on chromosome 20p13, which encodes RFVT3, the predominantly intestinal riboflavin transporter. 1 In contrast, BVVLS2 is caused by mutations in SLC52A2 gene on chromosome 8q24, which encodes RFVT2, the main riboflavin transporter in brain and spinal cord.
2,3 RFVT2 is highly expressed in brain and has been associated with neurodegenerative disorders. Maternal riboflavin deficiency due to mutations in SLC52A1/GPR172B gene (encoding RFVT1) is reported to cause a glutaric aciduria type 2-like condition in newborns. 4 The age at presentation of BVVLS2 varies from infancy to young adulthood. In infancy, initial symptoms often include neuropathy-mediated respiratory weakness. In children or young adults, sensorineural hearing loss may occur first, followed by other cranial neuropathies in combination with lower motor neuron signs and ataxia. Some cases may resemble amyotrophic lateral sclerosis. 5 In 2016, Jaeger and Bosch 6 published a review of 37 molecularly confirmed patients with BVVLS2. Typical biochemical abnormalities may include an abnormal acylcarnitine profile. Nerve conduction studies typically show axonal sensory motor neuropathies, and most patients reported thus far have had a normal brain MRI.
3 BVVLS2 can be differentiated from Fazio-Londe syndrome and amyotrophic lateral sclerosis, which do not involve sensorineural hearing loss. BVVLS2 can also be differentiated from Nathalie syndrome, which does not involve lower cranial nerve symptoms, and Bolthauser syndrome, which does not affect the lower motor neurons. Similarly, Madras motor neuron disease can be distinguished by the relatively benign course and most common occurrence in Southern India. The differential diagnosis also includes multiple acyl-CoA dehydrogenase deficiency, which lacks motor and sensory neuronopathies, and spinal muscle atrophy, which does not involve sensory nerves.
While the c.1327T>C genetic change in SLC52A2 seen in both of our patients has not been reported in patients with BVVLS2, their symptoms can be explained by this disorder (table 2) . Treatment with riboflavin has been shown to improve the clinical course in some individuals with this condition. 3 Both of the patients reported seem to have stabilized with riboflavin supplementation.
The mitochondrial c.1030C>T mutation in the TOP1MT gene (TOP1MT, mitochondrial DNA topoisomerase) found in both siblings could potentially explain some of the muscle biopsy features, including the small foci of subsarcolemmal staining in scattered fibers. This is less likely to be pathogenic, however, because the eldest asymptomatic sister is also homozygous for TOP1MT 1030C>T mutation. The PLEC1 gene mutations remain of unknown clinical significance in these cases.
The parents received extensive genetic counseling regarding the 25% recurrence risk of RTA type 1 and BVVLS2 among future children. The roles of preimplantation genetic diagnosis or invasive prenatal testing were discussed.
Conclusion
Our cases illustrate the pitfalls of single gene evaluations and support the necessity of more extensive testing in complex cases to identify multiple mutations that may potentially affect the clinical phenotype, and ultimately direct clinical management. In our cases, earlier exome sequencing would have obviated the need for invasive muscle biopsy. This study also highlights the importance of proper genetic counseling, both to explain complex variants of unknown significance, as well as to provide the family tools with which to guide future planning. 
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